Ewing's sarcoma: A combined approach in the management.

Abstract

Twenty-seven histologically confirmed cases of localised Ewing's sarcoma were treated by two different regimes. Radiotherapy alone was used in 13 cases and a combination of chemotherapy and radiotherapy in 14. Single agent chemotherapy (cyclophosphamide) was given sequentially in nine patients and cyclophosphamide and actinomycin-D in five. There is a significant difference in the response to these different regimes. Only 69.2% of patients treated by radiotherapy alone were disease-free, for a median period of 10.4 months and metastases were noticed in 53.8% of cases. The disease-free survival in patients treated by combination therapy (radiotherapy and chemotherapy) was 18.4 months and metastases were seen in only 42.9%. However, no metastases were seen in patients who received cyclophosphamide and actinomycin-D, during a period of 14 months and only one patient showed residual disease. It is concluded that the addition of cyclophosphamide alone is not adequate in the management of Ewing's sarcoma. Actinomycin-D in addition to cyclophosphamide has improved the disease-free survival period significantly. The optimum dose of radiotherapy and its combination with other chemotherapeutic agents needs further trials to find the best and most suitable schedule.

• Authors: G C Pant, B Sanyal, K Sahni, S M Tuli, T P Srivastava
• Journal: Clinical radiology (Clin Radiol) Vol. 32 Issue 4 Pg. 471-4 (Jul 1981) ISSN: 0009-9260 [Print] England
• PMID: 7249525 (Publication Type: Journal Article)

Chemical References

• Dactinomycin
• Cyclophosphamide

Topics

• Adolescent
• Adult
• Bone Neoplasms (radiotherapy)
• Child
• Child, Preschool
• Cyclophosphamide (therapeutic use)
• Dactinomycin (therapeutic use)
• Drug Therapy, Combination
• Female
• Follow-Up Studies
• Humans
• Male
• Radiotherapy Dosage
• Sarcoma, Ewing (radiotherapy)